Tramadol is used in children aged <12 years for analgesia, particularly for those at risk of obstructive sleep apnoea undergoing adenotonsillectomy. The Australian Therapeutic Goods Administration have strongly recommended that oral tramadol drops (100 mg/ml) not be used in children <12 years because of the risk of inadvertent overdose. The total mass of drug in a 10 ml bottle is 1000 mg. The only alternative preparation available is a 50 mg capsule that requires dispersion of a capsule's contents should smaller doses be required. The accuracy of this preparation has not been assessed. Twenty surgical ward nurses were asked to prepare a 15 mg dose of tramadol from a 50 mg capsule. The dose was within ±5% of 15 mg in 13 cases (65%) and within ±10% in 19 cases (95%) (range 13.9-17.1 mg). Despite the dose variability of this method of preparing tramadol, we consider it sufficiently accurate for clinical use. We also consider it safe, as even at the highest dose prepared, the variability would be unlikely to contribute to clinically significant side-effects or toxicity. Moreover, the maximal dose that could be administered is limited to the size of the capsule (50 mg).
Introduction
Tramadol is a synthetic phenylpiperidine analogue of codeine with centrally acting analgesic effects. It has been shown to be an effective analgesic in children for mild to moderate pain when prescribed at a dose of 1-2 mg/kg [1] [2] [3] [4] . Compared to other opioid analgesics, its advantages include a lower incidence of side-effects such as ventilatory depression, constipation and sedation 2, 5 . After paediatric tonsillectomy, tramadol has been found to have a similar analgesic effect to morphine, but with fewer episodes of oxygen desaturation in patients with obstructive sleep apnoea 3 . The lower incidence of respiratory side-effects has made tramadol a popular analgesic in the management of postoperative pain in children, particularly those with higher risk of respiratory complications. However, overdosage may result in seizures, apnoea, serotonin syndrome, cardiogenic shock and death 6 .
Medication errors are a frequent and recognised cause of actual or potential morbidity in the paediatric population. A systematic review has identified that when medication errors occur, they do so frequently during the drug preparation and administration phase within the paediatric population 7, 8 . Analgesics are also one of the most common classes of drugs involved. Errors in analgesic dosing can lead to excessive pain when underdosing, or unwanted side-effects when overdosing (e.g. nausea and vomiting) 9 .
In Australia, tramadol is licenced for use in children 12 years or older. It is frequently used off-licence in children under the age of twelve in the hospital setting. Five immediate-release preparations are available: 50 mg and 100 mg capsules and tablets and 100 mg/ml liquid in a 10 ml bottle. The concentrated liquid preparation has raised Therapeutic Goods Administration concern about the potential for inadvertent overdose. This was after the death of a two-year-old prescribed tramadol oral drops 10 . Consequently, at the Royal Children's Hospital in Melbourne, tramadol is supplied in either 50 mg or 100 mg capsules. To administer oral tramadol dosages of less than 50 mg, nursing staff are required to disperse the powdered contents of a 50 mg capsule in water and draw up the calculated dose into a syringe. The volume drawn up depends on the concentration the nurse has prepared.
This method of preparation and delivery of dose has not been audited previously. Thus, the accuracy, variability and likelihood of incorrect dosing of this method are currently unknown.
The aim of the study was to determine the accuracy and variance of tramadol dosing using the current preparation technique utilised by surgical nursing staff at the Royal Children's Hospital. We deemed a dose within 10% of the target dose to be clinically acceptable using this method of preparation.
Materials and methods
Approval to conduct a quality and safety audit of tramadol preparation by nursing staff was granted by the Royal Children's Hospital ethics committee (HREC 29060). Twenty nurses from an inpatient surgical ward volunteered to participate in this audit and their informed consent was obtained.
Participants were asked to prepare a mock 15 mg dose of tramadol using a 50 mg tramadol capsule, their choice of a 5 ml or 10 ml medication syringe, water for dilution and a medicine cup for mixing. An instruction sheet outlining how to prepare the mock 15 mg dose was also supplied.
The syringe size chosen, volume of diluent and level of nursing experience were recorded. Both the syringe containing the target 15 mg dose and the cup containing the remaining 35 mg were labelled and collected immediately and stored for analysis. A known mass of thymol marker was added to each mixing cup used by participants to prepare the assigned dose. The thymol allowed accurate calculation of initial diluent volume used if some volume was accidentally lost and to correct for potential measurement error as a result.
The concentration of tramadol was measured in both the syringe and mixing cup samples using high performance liquid chromatography (HPLC). A potential difference in drug mass between individual capsules was quantified by measuring both the syringe target dose and mixing cup residual drug samples.
Tramadol and thymol were determined simultaneously by HPLC with fluorescence detection. Mobile phase was 30% acetonitrile in 50 mM KH 2 PO 4 and 1 mM octane sulphuric acid at 1.5 ml/minute, with separation on a Waters Novapak C 18 column (150 x 3.9 mm), before detection at 235 nm excitation and 295 nm emission. The within-day coefficients of variation were 3.8% and 2.9% for tramadol (n=8) and thymol (n=8) respectively, at 1 mg/ml with a linear response to at least 10 mg/ml for both compounds.
Results
The mean tramadol dose prepared was 15.3 mg (range 13.9-17.1 mg, standard deviation [SD] 0.8 mg). The mean discarded drug within the mixing cups was 35.0 mg (range 32.2-37.8 mg, SD 1.6 mg) ( Table 1 ). The highest dose was 14% greater and the lowest, 7% lower than intended. The prepared dose was within 10% of the intended dose in 19/20 (95%) of mock preparations.
Discussion
In the twenty mock preparations, a dose within 5% (14.25-15.75 mg) of the assigned 15 mg target was achieved in 13 cases (65%) and within 10% (13.5-16.5 mg) in 19 cases (95%) of the samples prepared. This compares favourably to tramadol drops (100 mg/ml; 2.5 mg/drop) in which the manufacturer's maximal tolerable variability in the delivered dose is 0.25 mg/drop (10%).
Assuming the 15 mg dose was prepared for a 7.5 kg child (dose 2 mg/kg), the maximal dose observed in the audit (17.1 mg; 14% over the intended dose) could potentially lead to an excess of 8 mg per day if dosed at a regular six-hourly interval. This would result in approximately a further 1 mg/kg dose over a 24-hour period. Studies using a 3 mg/kg loading dose of tramadol for children undergoing surgery or dental extraction have found that dose to be superior to placebo and not associated with an increase in major side-effects 2,5 . Thus, the maximal dose seen within this audit would be unlikely to result in a clinically significant complication. It must be noted, however, that some cases of unwanted sideeffects of tramadol, including seizures, have been reported to the Australian Adverse Drug Reaction Advisory Committee at normal doses 6 .
Preparing the prescribed oral tramadol dose by dispersing the contents of a 50 mg capsule is also inherently safer than using tramadol 100 mg/ml drops because in the worst-case scenario, the maximal dose that could be administered is 50 mg, as compared to 1000 mg using drops. It also circumvents the potential to mistake 15 mg for 15 drops (37.5 mg) or 15 ml (1500 mg). Interestingly, the total mass of tramadol as measured from the syringe contents and mixing cup contents varied. These results found the average calculated mass of tramadol within a capsule was 50.3 mg (range 47.5-52.9 mg). A number of possibilities could explain this observation.
Firstly, the mass of active drug varies between separate batches and within individual capsules due to factors in the processing and manufacturing phase. The acceptable variation of active ingredients within tablets and capsules is outlined in the Therapeutic Goods Order No. 78 Standard for Tablets and Capsules, under section 10 of the Therapeutics Goods Act 1989. This is based on the drug monographs within the British Pharmacopoeia 2008 and United States Pharmacopeia 31st Ed -National Formulary 26th Ed. The principle of uniformity of dosage units assesses the mass of drug across a sample of 10 to 20 dosage units (capsules). The variation of tramadol mass across the 20 capsules would fall within the acceptance levels as outlined by the standards. Secondly, the contents of the capsule may not have been emptied properly or may have been lost prior to dissolution, which could account for some of the lower measurements obtained. Thirdly, the imprecision of the HPLC measurements (coefficient of variation) may have contributed.
It was not possible to relate the variability and accuracy of the dispersion method with that of the dose delivered by the built-in dropper device of the tramadol drops formulation, as the manufacturer Grunenthal GmbH (Aachen, Germany) considers divulging the variability in drop volume delivered commercially sensitive.
One limitation of this audit is that it did not set out to measure or confirm the variability in the mass of tramadol within the capsules themselves, only the resulting mock dose. Though some variation in individual capsule mass is to be expected during manufacture, the audit cannot determine how much the inter-capsule variation contributed to the observed differences in the samples. Despite the addition of thymol marker, this cannot completely correct for loss of diluent and/or capsule contents during the mixing phase. However, our findings reflect typical clinical practice in mixing medication, and thus are a realistic representation of paediatric tramadol dosing in the clinical setting.
The oral tramadol drops preparation available in Australia is licenced for use in children 12 years and older. The concentration is 100 mg/ml; it is supplied in a 10 ml bottle with a built-in dropper to deliver the required dose. A dose of 50 mg of tramadol is delivered in 20 drops (0.5 ml). This is one possible alternative to the capsule dispersion method we describe. However, given the highly concentrated formulation, an error in administration could potentially lead to a much greater dose of tramadol being accidentally delivered than the maximal 50 mg contained within one capsule. An alternate solution would be to supply liquid tramadol in a less concentrated solution. This would also facilitate administration via a nasogastric or gastrostomy tube when required.
Our institution's fact sheet containing instructions for preparing tramadol using this method can be found here: www.rch.org.au/uploadedFiles/Main/Content/pharmacy/ drug_information/Tramadol%20administration%20fact%20 sheet.pdf
In summary, the tramadol capsule dispersion method as utilised at our centre for doses below 50 mg was within 10% of the intended dose 95% of the time. We consider this to be sufficiently accurate for clinical use. We also consider it safe, as clinically relevant dose-related side-effects would be unlikely even after repeated dosing at the highest dose observed. It is also inherently safer than tramadol drops given that the maximum dose that could be administered inadvertently is limited to 50 mg.
